By 
Start with the premium. Germany’s Merck KGaA has agreed to acquire Minneapolis-based Bio-Techne, a provider of life science tools and analytical technologies, at $73 per share, a figure that carries a 36% premium to Bio-Techne’s one-month volume weighted average trading price. Total value: $11.3 billion. Joele Frank, Wilkinson Brimmer Katcher advised Bio-Techne.
The rest of the deal reads as a set of figures worth lining up. Bio-Techne carries more than 3,000 employees, about 2,300 of them in the United States, spread across 34 global locations and 15 manufacturing facilities in the U.S., Canada, the U.K., Switzerland and China. Merck KGaA employs more than 14,000 people in the U.S. across more than 70 company and customer sites. At $11.3 billion, the purchase ranks as Merck’s largest in more than a decade, its biggest since the 2015 acquisition of Sigma-Aldrich. The deal pushes Merck deeper into advanced biological research and into cell and gene therapy, corners of the life-science market growing faster than the broader industry.
New Merck CEO Kai Beckmann tied the acquisition to the company’s direction. He called Bio-Techne “an outstanding fit that directly supports our strategic direction focused on delivering cutting-edge products and solutions across the entire industry value chain-from lab customers to those manufacturing in the biotech and pharmaceutical industries.”
Bio-Techne chief Kim Kelderman put the case in terms of capacity. The deal, he said, gives the company “greater scale and expanded capabilities to accelerate innovation and deepen its impact. Together, we will empower our customers to tackle the most important challenges in science and healthcare, helping to improve outcomes worldwide.”
Two more numbers close the picture. Merck expects to save roughly 140 million euros in costs three years after closing, and plans to fund the purchase with existing cash and new debt while holding its investment-grade rating. The transaction is expected to close in late 2026 or early 2027.
Joele Frank, Wilkinson Brimmer Katcher’s Kelly Sullivan and Jamie Moser represented Bio-Techne.
Add the figures together and the shape of the deal comes clear: a German life-science giant paying a full premium to fold a mid-cap American supplier of proteins, antibodies and analytical instruments into a business that increasingly runs on cross-border scale. The catalog Bio-Techne brings, roughly 6,000 proteins and 425,000 antibodies, is the kind of recurring-revenue foundation buyers pay up for. Merck last reached this deep in 2015, when it bought Sigma-Aldrich for about $17 billion, and the Bio-Techne agreement signals a return to large-scale dealmaking in tools and reagents. At a 36% premium, Merck committed to it.
Comments